Industry News

Spotlight Innovation Inc. announced today that it has discontinued development of Immunoplex, an immune complex vaccine technology, in order to focus resources on developing other pipeline programs. Spotlight Innovation Inc. identifies and acquires rights to innovative, proprietary technologies designed to address unmet medical needs, with an emphasis on rare, emerging and neglected diseases. To find and evaluate unique..."/>
Spotlight Innovation Discontinues Immunoplex Development Program
Ligand Pharmaceuticals Incorporated partner Lundbeck announced today that the U.S."/>
Ligand Partner Lundbeck Receives FDA Approval of Carnexiv™ (carbamazepine) Injection as Intravenous Short-Term Replacement Therapy for Certain Seizure Types
Genmab A/S announced today that the U.S."/>
U.S. FDA Grants Priority Review for Daratumumab in Relapsed Multiple Myeloma
Medical Transcription Billing, Corp has acquired substantially all of US-based medical billing services firm MediGain's assets, the company said. Terms of the deal were not disclosed. These assets include customer accounts, intellectual property, and offshore operations in India and Sri Lanka."/>
MTBC Acquires Assets of Medical Billing Firm MediGain
DaVita Inc., a leading independent medical group and a leading provider of kidney care services in the United States, today announced that it will hold its quarterly conference call to discuss third quarter results on Wednesday, November 2, 2016, at 5:00 p.m. Eastern Time. The company plans to release its results after market close the same day. This call is also being webcast and can be accessed at the DaVita IR web page."/>
DaVita Inc. Schedules 3rd Quarter 2016 Investor Conference Call
Ensign Group, which has skilled nursing, rehabilitative care services, hospice care, assisted living and urgent care companies, has sold its 14 urgent care operations in the Seattle region. MultiCare Health System, a nonprofit healthcare group, bought the operations for undisclosed terms. "While we still believe urgent care is an important healthcare service, we determined that we can better use our resources by focusing on the post-acute continuum,..."/>
BRIEF: Ensign Group sells urgent care operations [The Orange County Register]
Gemphire Therapeutics Inc., a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for the treatment of dyslipidemia, a serious medical condition that increases the risk of life threatening cardiovascular disease, today announced that on October 3, 2016, the Compensation Committee of its Board of Directors, which is composed entirely of independent directors, approved three equity awards under..."/>
Gemphire Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Select Medical Holdings Corporation, will release the financial results for its third quarter ended September 30, 2016 on Thursday, November 3, 2016 after the market closes. Select Medical will host a conference call regarding its third quarter results, as well as its business outlook, on Friday, November 4, 2016, at 9:00am ET. The domestic dial in number for the call is 1-877-430-7741. The international dial in number is 1-615-247-0054...."/>
Select Medical Holdings Corporation to Announce Third Quarter 2016 Results on Thursday, November 3
Fulgent Genetics, Inc. announced today that the underwriters of its previously announced initial public offering have exercised in full their option to purchase 630,000 additional shares of the company’ s common stock at a public offering price of $9.00 per share, before underwriting discounts. All of the additional shares were offered by Fulgent Genetics.. Credit Suisse Securities LLC and Piper Jaffray& Co. acted as joint book-running managers..."/>
Fulgent Genetics, Inc. Announces Full Exercise of Option to Purchase Additional Shares in its Initial Public Offering
IIROC Trading Halt - I
OrganiGram Holdings Inc. announces that subject to the approval of the TSX Venture Exchange, the Company shall satisfy transaction success fees payable to XIB by issuing 106,430 of Common Shares in the capital of OrganiGram to XIB. The Common Shares will be issued at a price of $1.72 per share. Any issuance of shares will be subject to applicable hold periods required under securities laws."/>
OrganiGram Announces Issuance of Shares for Services Performed
Seres Therapeutics, Inc. in the U.S. District Court for the District of Massachusetts. The complaint is brought on behalf of all purchasers of Seres securities between June 25, 2015 and July 29, 2016, for alleged violations of the Securities Exchange Act of 1934 by Seres's officers and directors."/>
Robbins Arroyo LLP: Seres Therapeutics, Inc. (MCRB) Misled Shareholders According to a Recently Filed Class Action
Lipocine Inc., a specialty pharmaceutical company, today announced that U.S. District Court in Delaware granted our motion to dismiss a lawsuit filed by Clarus Therapeutics, Inc.. Clarus claimed that LPCN 1021 infringed Clarus’ patent."/>
Lipocine Wins Dismissal of Patent Infringement Lawsuit Related to LPCN 1021
Sienna Senior Living Inc. today announced that it will report its 2016 third quarter results after market close on Wednesday, November 9, 2016. Lois Cormack, President and CEO, and Nitin Jain, Executive Vice President and CFO, will host a conference call for the investment community the following day, Thursday, November 10, 2016 at 11:00 a.m.. The call-in numbers for participants are 416-340-2219 or 866-225-2055. A webcast of the call will be accessible via Sienna's website at:..."/>
Sienna Announces Q3 2016 Results Release Date and Conference Call
Teladoc, Inc. is providing free general medical care to victims of Hurricane Matthew evacuation zones. Services will be delivered remotely via Teladoc’ s telehealth platform. Individuals residing in the evacuation zones can access care by calling the dedicated hotline for their state:."/>
Teladoc Provides Telehealth Services to Hurricane Matthew Evacuation Zones
Seres Therapeutics, Inc. concerning the Company and its officers’ possible violations of federal securities laws. GPM is preparing a lawsuit on behalf of injured investors. Seres is a microbiome therapeutics platform company that focuses on the development of biological drugs designed to restore health by repairing the function of a dysbiotic microbiome."/>
Glancy Prongay & Murray Commences Investigation on Behalf of Seres Therapeutics, Inc. Investors
Aetna Foundation Donates $100,000 to Disaster Relief--. HARTFORD, Conn.---- Aetna is offering resources to members who have been affected by Hurricane Matthew in Florida, Georgia, South Carolina and North Carolina. If necessary, affected Aetna members may refill their prescriptions early."/>
Aetna Makes Resources Available to Members Affected by Hurricane Matthew
Centene Corp. concerning the Company and its officers’ possible violations of federal securities laws. Injured investors are encouraged to contact The Wagner Firm to discuss their legal rights, and a potential class action lawsuit to recover investors’ losses. On March 24, 2016, Centene issued a press release announcing the acquisition of Health Net, Inc. a health care..."/>
INVESTOR ALERT: Investigation of Centene Corp. Announced by The Wagner Firm

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Most Popular Sectors in the News
Sectors Articles in the last 7 days
Information Technology643 Articles
Consumer Discretionary601 Articles
Financials567 Articles
Health Care407 Articles
Industrials390 Articles

Sponsored Financial Commentaries

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact , please visit . Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at